Parameswaran Hari

Company: Obsidian Therapeutics

Job title: Chief Development Officer

Seminars:

OBX-115 Engineered TIL with Regulatable Membrane- Bound IL15: Translational Data from Patients with Advanced Melanoma 12:00 pm

OBX-115 is a highly differentiated TIL cell therapy with optimized characteristics for response and persistence This data confirms successful platform validation, supporting the proposed OBX-115 mechanism of action ACZ dose-driven regulatable mbIL15 expression on OBX-115 enables elimination of IL2 from the regimen and the potential for a safer, more effective TIL cell therapyRead more

day: Conference Day One CMC Track AM